ROIV Roivant Sciences Ltd

$11.81

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Roivant Sciences Ltd

No Company Description Available

Website: N/A

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
March
CIK
1635088
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11, BM
Valuation
Market Cap
$7.24B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
1.40
Performance
EPS
$-1.00
Dividend Yield
—
Profit Margin
-95.10%
ROE
-14.60%
Technicals
50D MA
$10.40
200D MA
$11.25
52W High
$13.05
52W Low
$8.73
Fundamentals
Shares Outstanding
714M
Target Price
$16.00
Beta
1.25

ROIV EPS Estimates vs Actual

● Estimated
● Actual

ROIV News & Sentiment

Aug 12, 2025 • Motley Fool SOMEWHAT-BULLISH
Why Roivant Sciences Stock Bounced Back on Tuesday
Investors were in a forgiving mood after Monday's dispiriting earnings release.
Aug 11, 2025 • Motley Fool NEUTRAL
Why Roivant Sciences Stock Was Slipping on Monday
The distinctive biotech wasn't a sector favorite as the trading week began.
Aug 11, 2025 • Zacks Commentary NEUTRAL
Roivant Sciences Ltd. ( ROIV ) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +21.74% and -71.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 07, 2025 • Zacks Commentary NEUTRAL
Kura Oncology ( KURA ) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 05, 2025 • Zacks Commentary NEUTRAL
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 23, 2025 • Benzinga SOMEWHAT-BULLISH
What Does the Market Think About Roivant Sciences? - Roivant Sciences ( NASDAQ:ROIV )
Roivant Sciences's ROIV short percent of float has fallen 8.84% since its last report. The company recently reported that it has 41.10 million shares sold short, which is 8.25% of all regular shares that are available for trading.
Sentiment Snapshot

Average Sentiment Score:

0.163
50 articles with scored sentiment

Overall Sentiment:

Bullish

ROIV Reported Earnings

Feb 11, 2025
Dec 31, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.24
  • Whisper: —
  • Surprise %: 17.2%
Nov 12, 2024
Sep 30, 2024 (Pre market)
-0.05 Surprise
  • Reported EPS: $-0.31
  • Estimate: $-0.26
  • Whisper: —
  • Surprise %: -20.4%
Aug 08, 2024
Jun 30, 2024 (Pre market)
0.38 Surprise
  • Reported EPS: $0.12
  • Estimate: $-0.26
  • Whisper: —
  • Surprise %: 146.2%
May 30, 2024
Mar 31, 2024 (Pre market)
0.11 Surprise
  • Reported EPS: $-0.19
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: 36.7%
Feb 13, 2024
Dec 31, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.30
  • Estimate: $-0.32
  • Whisper: —
  • Surprise %: 6.2%
Nov 13, 2023
Sep 30, 2023 (Pre market)
-0.09 Surprise
  • Reported EPS: $-0.40
  • Estimate: $-0.31
  • Whisper: —
  • Surprise %: -29.0%
Aug 14, 2023
Jun 30, 2023 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.38
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: -26.7%
Jun 28, 2023
Mar 31, 2023 (Pre market)
0.16 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.36
  • Whisper: —
  • Surprise %: 44.4%
Feb 13, 2023
Dec 31, 2022 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.49
  • Estimate: $-0.39
  • Whisper: —
  • Surprise %: -25.6%

Financials